Robin Norris, MD, MS, MPH

Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1). Raetz, EA; Teachey, DT; Minard, C; Liu, X; Norris, RE; Denic, KZ; Reid, J; Evensen, NA; Gore, L; Fox, E; et al. Pediatric Blood and Cancer. 2023; 70:e30609.

Clinical trials: A plea to cooperative groups, consortia, pharmaceutical companies, and lead investigators for reasonable imaging protocols. Trout, AT; Norris, RE; de Blank, PM K; Backus, LR; Towbin, AJ; Nash, JM. Pediatric Blood and Cancer. 2023; 70:e30362.

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma. Forlenza, CJ; Rosenzweig, J; Mauguen, A; Buhtoiarov, I; Cuglievan, B; Dave, H; Deyell, RJ; Flerlage, JE; Franklin, AK; Krajewski, J; et al. Blood Advances. 2023; 7:3225-3231.

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Rubinstein, JD; Breese, EH; Krupski, MC; O'Brien, MM; Dandoy, CE; Mizukawa, B; Khoury, R; Norris, RE; Davies, SM; Phillips, CL. Transplantation and cellular therapy. 2023; 29:311.e1-311.e7.

Barriers to medication adherence among adolescents and young adults with cancer. McGrady, ME; Ketterl, TG; Norris, RE; Perentesis, JP; Pettee, D; Mara, CA; Breen, G; Pai, AL H. Pediatric Blood and Cancer. 2023; 70:e30186.

Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Burke, GA A; Vinti, L; Kabickova, E; Beishuizen, A; Tacyildiz, N; Uyttebroeck, A; Kang, HJ; Luisi, F; Minard-Colin, V; Burkhardt, B; et al. Blood Advances. 2023; 7:602-610.

Adherence and Barriers to Inpatient Physical Therapy Among Adolescents and Young Adults with Hematologic Malignancies. McGrady, ME; Perez, MN; Bernstein, J; Strenk, M; Kiger, MA; Norris, RE. Journal of Adolescent and Young Adult Oncology. 2022; 11:605-610.

P1088: UPDATED DATA FROM A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN COMBINED WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA. Locatelli, F; Luisi, F; Pianovski, M; Salvino, MA; Fagioli, F; Epelman, S; Britto De Abreu Lima, L; Norris, R; Odone Filho, V; Zecca, M; et al. HemaSphere. 2022; 6:978-979.

Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis. Forlenza, CJ; Rosenzweig, J; Mauguen, A; Buhtoiarov, I; Cuglievan, B; Dave, H; Deyell, RJ; Flerlage, J; Franklin, A; Krajewski, J; et al. Blood. 2021; 138:2465.

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; et al. Pediatric Blood and Cancer. 2021; 68:e29126.